NYSE:TFX
TELEFLEX INC
A leading global provider of disposable medical devices and equipment serving critical care, cardiovascular, and surgical markets worldwide.
Key Metrics
Investment Thesis
Bull Case
Teleflex possesses a dominant market position with high barriers to entry in specialized medical device categories; The company's strong free cash flow generation supports shareholder returns through dividends and share repurchases totaling $360.3M last year; Long-term secular trends favoring minimally invasive procedures support future revenue growth above the recent base.
Bear Case
The massive one-time loss from discontinued operations distorts 2025 profitability metrics and raises concerns about strategic restructuring costs; High leverage ratios with $3.64B total debt against current assets of $1.94B limit financial flexibility in a rising rate environment; Recent revenue contraction to $1.99B from $3.05B the prior year signals potential cyclicality or demand headwinds.
About TELEFLEX INC
Teleflex Inc. (TFX) designs, manufactures, and markets disposable medical devices and equipment primarily serving healthcare facilities and ambulatory surgical centers globally. The company focuses on innovative solutions across critical care, cardiovascular, endoscopy, and urology segments. With a revenue of $1.99B in 2025, the firm continues to leverage its extensive product portfolio and global reach.
Analysis
Management Discussion
While the company generated positive operating profit of $118.4M, reported net income turned negative at $-905.6M in 2025 due to discontinued operations losses of $964.2M. Cash flow from operations remained healthy at $340.7M despite substantial capital expenditures of $95.2M and debt issuances of $1.14B, resulting in a net cash increase of $126.2M.
Industry Overview
The global medical devices market is characterized by steady growth driven by aging populations and technological advancements in minimally invasive surgery. Competition is fierce among established players like Medtronic and Johnson & Johnson, yet disposable device segments remain lucrative due to recurring replacement cycles. Regulatory approval processes are rigorous but essential for maintaining trust in life-saving equipment.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $2.79B | $2.97B | $3.05B | $1.99B |
| Cost of Revenue | $1.26B | $1.33B | $1.34B | $872.0M |
| Gross Profit | $1.53B | $1.65B | $1.70B | $1.12B |
| Operating Expenses | $1.03B | $1.14B | $1.55B | $1.00B |
| Operating Income | $499.7M | $506.3M | $151.0M | $118.4M |
| R&D | $153.8M | $154.4M | $161.7M | $144.8M |
| G&A | $863.7M | $929.9M | $995.3M | $720.2M |
| Stock-Based Comp | $27.2M | $31.5M | $31.3M | $25.7M |
| D&A | $230.6M | $242.1M | $274.6M | $177.7M |
| Depreciation | $66.5M | $68.1M | $76.9M | $56.1M |
| Amortization | $164.1M | $174.0M | $197.7M | $121.7M |
| Other OpEx | $13.8M | $56.4M | $394.7M | $137.4M |
| Non-Operating Income | $-53.8M | $-72.3M | $-75.5M | $-93.8M |
| Interest Expense | $54.3M | $85.1M | — | — |
| Interest Income | $912.0K | $12.8M | $8.0M | $6.4M |
| Pre-Tax Income | $445.9M | $434.0M | $75.5M | $24.6M |
| Income Tax | $83.0M | $76.4M | $5.3M | $-34.0M |
| Continuing Ops | $362.9M | $357.6M | $70.2M | $58.5M |
| Discontinued Ops | $223.0K | $-1.2M | $-487.0K | $-964.2M |
| Net Income | $363.1M | $356.3M | $69.7M | $-905.6M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $363.1M | $356.3M | $69.7M | $-905.6M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $1.41B | $1.41B | $1.47B | $1.94B |
| Cash & Equivalents | $292.0M | $222.8M | $290.2M | $378.6M |
| Accounts Receivable | $408.8M | $443.5M | $459.5M | $345.6M |
| Inventory | $578.5M | $626.2M | $600.1M | $404.4M |
| Prepaid Expenses | $125.1M | $107.5M | $117.9M | $150.7M |
| Other Current Assets | $6.5M | $7.4M | $3.5M | $659.1M |
| Long-Term Assets | $5.52B | $6.13B | $5.63B | $5.01B |
| PP&E (Net) | $447.2M | $479.9M | $502.9M | $498.3M |
| Intangibles | $2.31B | $2.50B | $2.27B | $1.52B |
| Goodwill | $2.54B | $2.91B | $2.63B | $2.31B |
| Operating Leases | $131.2M | $123.5M | $108.9M | $91.8M |
| Other LT Assets | $95.8M | $105.7M | $114.0M | $589.6M |
| Total Assets | $6.93B | $7.53B | $7.10B | $6.95B |
| Current Liabilities | $581.5M | $606.7M | $649.4M | $762.0M |
| Accounts Payable | $126.8M | $132.2M | $141.0M | $130.2M |
| Current Debt | $87.5M | $87.5M | $100.0M | $100.0M |
| Taxes Payable | $24.7M | $41.5M | $41.3M | $18.8M |
| Other Current Liab | $201.8M | $198.7M | $223.8M | $395.7M |
| Long-Term Liabilities | $2.32B | $2.48B | $2.17B | $3.06B |
| Long-Term Debt | $1.62B | $1.73B | $1.56B | $2.54B |
| LT Operating Leases | $120.4M | $111.3M | $99.2M | $84.2M |
| Other LT Liab | $580.1M | $645.9M | $515.4M | $434.8M |
| Total Liabilities | $2.91B | $3.09B | $2.82B | $3.82B |
| Shareholders' Equity | $4.02B | $4.44B | $4.28B | $3.12B |
| Paid-In Capital | $715.1M | $749.7M | $781.2M | $815.8M |
| Retained Earnings | $3.82B | $4.11B | $4.12B | $3.15B |
| AOCI | $-403.5M | $-314.4M | $-316.7M | $-239.5M |
| Treasury Stock | $154.9M | $152.1M | $350.3M | $649.5M |
| Total L&E | $6.93B | $7.53B | $7.10B | $6.95B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $363.1M | $356.3M | $69.7M | $-905.6M |
| Non-Cash Adjustments | $-52.5M | $129.6M | $601.9M | $1.25B |
| Working Capital Changes | $31.5M | $24.7M | $-35.8M | $-6.9M |
| Cash from Operations | $342.1M | $510.6M | $635.7M | $340.7M |
| Capital Expenditures | $79.2M | $91.4M | $126.4M | $95.2M |
| Cash from Investing | $-257.9M | $-621.2M | $-99.4M | $-849.2M |
| Debt Issuances | $744.2M | $646.0M | $130.0M | $1.14B |
| Debt Repayments | $884.5M | $544.8M | $291.5M | $153.0M |
| Share Buybacks | — | — | $200.0M | $300.0M |
| Dividends Paid | $63.8M | $63.9M | $63.5M | $60.3M |
| Cash from Financing | $-217.5M | $38.5M | $-421.9M | $611.5M |
| FX Effect | $-19.7M | $2.9M | $-9.7M | $23.2M |
| Net Change in Cash | $-153.1M | $-69.2M | $104.8M | $126.2M |
| Beginning Cash | $445.1M | $292.0M | $222.8M | $285.3M |
| Ending Cash | $292.0M | $222.8M | $327.6M | $402.7M |
Frequently Asked Questions
How does TELEFLEX INC make money?
Critical Care and Monitoring solutions for intensive therapy units; Cardiovascular and Electrophysiology devices for heart surgery; Endoscopy and Gastroenterology tools for minimally invasive procedures; Urology instruments for renal and pelvic surgeries.
What are the main risks for TFX?
Significant decline in 2025 net income of $905.6M impacting retained earnings which now show a $3.15B deficit; Heavy reliance on debt financing evidenced by $2.54B long-term debt and recent cash flow shifts; Potential regulatory scrutiny on disposable medical device pricing and safety standards.
What is TFX's competitive advantage?
Extensive global distribution network ensuring rapid market penetration and service support; Strong intellectual property portfolio with proprietary disposable technologies that command premium pricing; Deep relationships with top-tier hospital systems driving high switching costs.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.